White powder Sild enafil Man Sex Enhancement Hormones Sild enafil citrate CAS: 139755-83-2

Description:

Silde afil, sold as  and other trade names, is a medication used to treat erectile dysfunctionandpulmonary arterial hypertension. Its effectiveness for treating dysfunction in women has not been demonstrated.

Silden afil relaxes muscles found in the walls of blood vessels and increases blood flow to particular areas of the body.

Silden afil under the name  is used to treat erectile dysfunction (impotence) in men.

Another brand of sild enafil is Revatio, which is used to treat pulmonary arterial hypertension and improve exercise capacity in men and women.

Quick details:

Chemical name: Sildena fil 
CAS: 139755-83-2
Assay: 99% min.
Molecular formula: C22H30N6O4S
Molecular weight: 474.58
Packing: 1kg net/foil bag, 5kg/drum.
Delivery: Express courier.
Character: White or almost white crystalline powder, odorless, bitter astringent taste, insoluble in water and ethanol.

Usage:

1. Treating high blood pressure in the lungs (pulmonary arterial hypertension [PAH]). It may also be used for other conditions as determined by your doctor.

2. Sil denafil is a phosphodiesterase type 5 (PDE5) inhibitor. It works by relaxing and dilating the blood vessels in the lungs. This lowers the blood pressure in the lungs and helps to improve your ability to exercise.

Application:

Sild enafil citrate, sold as Via gra, Revatio and under various other trade names, is a drug used to treat erectile dysfunction and pulmonary arterial hypertension (PAH). It was originally discovered by Pfizer scientists Andrew Bell, David Brown, and Nicholas Terrett.

The primary indication of sildena fil is treatment of erectile dysfunction (inability to sustain a satisfactory erection to complete intercourse). Its use is now standard treatment for erectile dysfunction in all settings, including diabetes.

In clinical trials, the most common adverse effects of silde nafil use included headache, flushing, dyspepsia, nasal congestion and impaired vision, including photophobia and blurred vision.Some sild enafil users have complained of seeing everything tinted blue (cyanopsia).Some complained of blurriness and loss of peripheral vision. In July 2005, the FDA found that silde nafil could lead to vision impairment in rare cases and a number of studies have linked silde nafil use with nonarteritic anterior ischemic optic neuropathy.

Rare but serious adverse effects found through postmarketing surveillance include priapism, severe hypotension, myocardial infarction (heart attack), ventricular arrhythmias, stroke, increased intraocular pressure, and sudden hearing loss. As a result of these postmarketing reports, in October 2007, the FDA announced that the labeling for all PDE5 inhibitors, including sild enafil, required a more prominent warning of the potential risk of sudden hearing loss.